Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses.

ABSTRACT: Lassa fever (LF), a viral hemorrhagic fever disease with a case fatality rate that can be over 20% among hospitalized LF patients, is endemic to many West African countries. Currently, no vaccines or therapies are specifically licensed to prevent or treat LF, hence the significance of developing therapeutics against the mammarenavirus Lassa virus (LASV), the causative agent of LF. We used in silico docking approaches to investigate the binding affinities of 2015 existing drugs to LASV proteins known to play critical roles in the formation and activity of the virus ribonucleoprotein complex (vRNP) responsible for directing replication and transcription of the viral genome. Validation of docking protocols were achieved with reference inhibitors of the respective targets. Our in silico dockin

SUBMITTER: Ofodile CA 

PROVIDER: S-EPMC11768584 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature